The latest OVATION-2 trial update, presented at the American Society of Clinical Oncology 2025 annual meeting, shows that adding intraperitoneal IMNN-001 to standard neoadjuvant chemotherapy improved both...
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A retrospective analysis from Memorial Sloan Kettering links higher patient-reported pain to increased emergency department utilization among individuals newly diagnosed with ovarian cancer. This study was...
Real-world data show a rise in biomarker testing for primary advanced/recurrent endometrial cancer, especially mismatch repair/microsatellite instability, but disparities in access persist across care...
A phase 3 trial subgroup analysis found that adding pembrolizumab to adjuvant chemotherapy may improve disease-free survival in patients with mismatch repair-deficient endometrial cancer, a population at...
A randomized trial found that radiation therapy alone provides better progression-free survival and fewer acute toxicities than chemoradiation for women with localized recurrent endometrial cancer.
Researchers developed a retrospective cohort study to examine the reoperation rates and health care costs associated with reoperation for patients who underwent breast-conserving surgery.
